MRC1 and ovarian serous adenocarcinoma: The extent to which defective MMR contributes to therapy resistance in vivo, however, is inconclusive [79] for high grade serous ovarian cancer, but is better defined in ovarian clear cell carcinoma where defective MMR plays a larger role in oncogenesis [80].